Conclusive evidence of its efficacy and safety in humans requires additional clinical trials
Several mechanisms might explain possible benefits: Improved glycaemic control : Better blood glucose regulation may reduce endothelial dysfunction and microvascular damage, both implicated in ED pathophysiology Weight reduction : Significant weight loss can improve testosterone levels, reduce inflammation, and enhance vascular function Cardiovascular effects : GLP-1 agents may improve endothelial function and reduce cardiovascular risk factors that contribute to ED Reduced inflammation : These medications have been associated with anti-inflammatory effects that might benefit vascular health, though more research is needed Some observational studies have reported improvements in erectile function scores among men with diabetes treated with GLP-1 receptor agonists, though the evidence is limited and more robust research is needed
GLP-1 receptors are found in the heart and blood vessels, influencing blood pressure, lipid profiles and inflammation
Common adverse events included diarrhea, vomiting, and constipation (more common for those on the highest dose)
A subsequent study confirmed that heterologous expression of P9 increases GLP-1 secretion from intestinal L cells in a dose-dependent manner